title: Monitoring - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 182/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Monitoring
  Digoxin has 11 different methodologies reported Australia and New Zealand laboratories for therapeutic drug monitoring (TDM). Digoxin immunoassays may have a problem with interference from digoxin-like immunoreactive factors, spironolactone, canrenoate, digoxin metabolites and steroids.[29]
  References
  |
  Chia N, Fulcher J, Keech A. Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): An evidence-based mnemonic for the treatment of systolic heart failure. Internal Medicine Journal. 2016;46:653-62.
  Hood WB, Jr., Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of heart failure in patients in sinus rhythm. [Review][Update of Cochrane Database Syst Rev. 2004;(2):CD002901; PMID: 15106182]. 2014;1:Cd002901.
  Alajaji W, Baydoun A, Al-Kindi SG, Henry L, Hanna MA, Oliveira GH. Digoxin therapy for cor pulmonale: A systematic review. International Journal of Cardiology. 2016;223:320-4.
  Ahuja RS, Ramakrishnan S, Kothari SS, Bhatt K, Gupta SK, Juneja R, Saxena A, Bahl VK. Propranolol in infants with ventricular septal defect with heart failure(VSD-phf study). Annals of Pediatric Cardiology. 2013;6 (1):105-6.
  Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology. 2017;70:1262-72.
  Buchhorn R, Hulpke-Wette M, Hilgers R, Bartmus D, Wessel A, Bursch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. International Journal of Cardiology. 2001;79:167-73.
  Ghader FR, Abaskhanian A. Influence of metoprolol on systolic and diastolic function in children with heart failure. Pakistan Journal of Biological Sciences. 2009;12:451-4.
  Azeka E, Franchini Ramires JA, Valler C, Bocchi EA. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. Journal of the American College of Cardiology. 2002;40:2034-8.
  Zhang X, Sun Y, Xiao Y, Sun J, Huang M, Chen S, Liu F. The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: A prospective, randomized-controlled study. Pediatric Cardiology. 2013;34:680-5.
  Rossano JW, Cabrera AG, Jefferies JL, Naim MPHMY, Humlicek T. Pediatric cardiac intensive care society 2014 consensus statement: Pharmacotherapies in cardiac critical care chronic heart failure. Pediatric Critical Care Medicine. 2016;17:S20-S34.
  Management of supraventricular tachycardia in children 2018: https://www.uptodate.com/.../management-of-supraventricular-tachycardia-in-children.
  Sanatani S, Potts JE, Reed JH, Saul JP, Stephenson EA, Gibbs KA, Anderson CC, MacKie AS, Ro PS, Tisma-Dupanovic S, Kanter RJ, Batra AS, Fournier A, Blaufox AD, Singh HR, Ross BA, Wong KK, Bar-Cohen Y, McCrindle BW, Etheridge SP. The study of antiarrhythmic medications in infancy (SAMIS): A multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circulation: Arrhythmia and Electrophysiology. 2012;5:984-91.
  Hornik CP, Chu PY, Li JS, Clark RH, Smith PB, Hill KD. Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants. Pediatr Crit Care Med. 2014;15:839-45.
  Bolin EH, Lang SM, Tang X, Collins RT. Propranolol Versus Digoxin in the Neonate for Supraventricular Tachycardia (from the Pediatric Health Information System). Am J Cardiol. 2017;119:1605-10.
  ANZCOR Guideline 12.5 – Management of Specific Dysrhythmias in Paediatric Advanced Life Support. https://resus.org.au/wpfb-file/anzcor-guideline-12-5-management-of-spec-dys-aug16-pdf/ 2016.
  Atrial tachyarrhythmias in children. 2018. https://www.uptodate.com/contents/atrial-tachyarrhythmias-in-children.
  Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatrics. 1977;59:250-6.
  Tikanoja T, Kirkinen P, Nikolajev K, Eresmaa L, Haring P. Familial atrial fibrillation with fetal onset. Heart. 1998;79:195-7.
  Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS ONE. 2018;13 (3) (no pagination).
  Casey FA, McCrindle BW, Hamilton RM, Gow RM. Neonatal atrial flutter: significant early morbidity and excellent long-term prognosis. Am Heart J. 1997;133:302-6.
  Texter KM, Kertesz NJ, Friedman RA, Fenrich AL, Jr. Atrial flutter in infants. Journal of the American College of Cardiology. 2006;48:1040-6.
  Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ (Clinical research ed). 2015;351:h4451.
  Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. European Journal of Clinical Pharmacology. 2018;74:819-32.
  Mulla N, Karpawich PP. Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin. Pediatr Emerg Care. 1995;11:238-9.
  Mladenka P, Applova L, Patocka J, Costa VM, Remiao F, Pourova J, Mladenka A, Karlickova J, Jahodar L, Voprsalova M, Varner KJ, Sterba M. Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal Research Reviews. 2018;38:1332-403.
  Truhlar A, Deakin CD, Soar J, Khalifa GE, Alfonzo A, Bierens JJ, Brattebo G, Brugger H, Dunning J, Hunyadi-Anticevic S, Koster RW, Lockey DJ, Lott C, Paal P, Perkins GD, Sandroni C, Thies KC, Zideman DA, Nolan JP, Cardiac arrest in special circumstances section C. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation. 2015;95:148-201.
  Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; March 3rd, 2017.
  Richardson C, Silver ES. Management of Supraventricular Tachycardia in Infants. Paediatr Drugs. 2017;19:539-51.
  Norris RL, Martin JH, Thompson E, Ray JE, Fullinfaw RO, Joyce D, Barras M, Jones GR, Morris RG. Current status of therapeutic drug monitoring in Australia and New Zealand: A need for improved assay evaluation, best practice guidelines, and professional development. Therapeutic Drug Monitoring. 2010;32:615-23.
  Australian Injectable Drugs Handbook, 7th Edition. Accessed 29/08/2018: https://aidh.hcn.com.au/
  Australian Medicines Handbook. Accessed 29/08/2018: https://amhonline.amh.net.au.acs.hcn.com.au/
  MIMSOnline. Accessed 29/08/2018: https://www.mimsonline.com.au.acs.hcn.com.au/
  Mclachlan A, Ramzan I. Meals and medicines. Australian Prescriber 2006;29:40-42. https://www.nps.org.au/assets/47171dee404e1be5-e9be7f6e0cf2-f63c4030b61d1139331706218a82a9ed1e2b5fa8bce5df07bc9a064b3b3f.pdf
  |
  Original version Date: 22/4/2019
  |
  Author: NeoMed Consensus Group
  |
  Current Version number: 1
  |
  Current Version Date: 22/4/2019
  |
  Risk Rating: Low
  |
  Due for Review: 22/4/2024
  |
  Approved by: DTC
  |
  Approval Date: TBA
  |
  |
  | |